AU2002235141A1 - Glycosyltransferase vectors for treating cancer - Google Patents
Glycosyltransferase vectors for treating cancerInfo
- Publication number
- AU2002235141A1 AU2002235141A1 AU2002235141A AU3514102A AU2002235141A1 AU 2002235141 A1 AU2002235141 A1 AU 2002235141A1 AU 2002235141 A AU2002235141 A AU 2002235141A AU 3514102 A AU3514102 A AU 3514102A AU 2002235141 A1 AU2002235141 A1 AU 2002235141A1
- Authority
- AU
- Australia
- Prior art keywords
- glycosyltransferase
- vectors
- treating cancer
- cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000051366 Glycosyltransferases Human genes 0.000 title 1
- 108700023372 Glycosyltransferases Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01087—N-Acetyllactosaminide 3-alpha-galactosyltransferase (2.4.1.87), i.e. alpha-1,3-galactosyltransferase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25339500P | 2000-11-27 | 2000-11-27 | |
| US60/253,395 | 2000-11-27 | ||
| PCT/US2001/044306 WO2002042468A2 (en) | 2000-11-27 | 2001-11-26 | Glycosyltransferase vectors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002235141A1 true AU2002235141A1 (en) | 2002-06-03 |
Family
ID=22960093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002235141A Abandoned AU2002235141A1 (en) | 2000-11-27 | 2001-11-26 | Glycosyltransferase vectors for treating cancer |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6713055B2 (en) |
| AU (1) | AU2002235141A1 (en) |
| WO (1) | WO2002042468A2 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003099859A2 (en) | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| ATE462449T1 (en) | 2002-10-09 | 2010-04-15 | Central Iowa Health System | USE OF ALPHA (1,3)-GALACTOSYLTRANSFERASE-EXPRESSING ALLOGENIC TUMOR CELLS FOR VACCINATION AGAINST TUMORS |
| US20050201993A1 (en) * | 2002-10-09 | 2005-09-15 | Link Charles J.Jr. | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| US8951772B2 (en) * | 2002-10-15 | 2015-02-10 | Per Sonne Holm | Adenoviruses, nucleic acids coding therefor, and use thereof |
| US7153650B2 (en) | 2003-03-13 | 2006-12-26 | Geron Corporation | Marker system for preparing and characterizing high-quality human embryonic stem cells |
| US7598077B2 (en) | 2003-06-05 | 2009-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for enhancing differential expression |
| US7662101B2 (en) * | 2003-09-18 | 2010-02-16 | Cardiac Pacemakers, Inc. | Therapy control based on cardiopulmonary status |
| US20070110719A1 (en) | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses |
| CN100361710C (en) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF |
| JP5855326B2 (en) | 2005-01-06 | 2016-02-09 | ノヴォ ノルディスク アー／エス | Anti-KIR combination therapy and method |
| CA2601187A1 (en) * | 2005-03-09 | 2006-09-14 | Board Of Regents, The University Of Texas System | Novel htmc promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes |
| EP1866338B1 (en) | 2005-03-23 | 2016-09-21 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| ES2732278T3 (en) | 2006-09-26 | 2019-11-21 | Genmab As | Anti-CD38 plus corticosteroids plus a non-corticosteroid chemotherapeutic agent for the treatment of tumors |
| US7998486B2 (en) * | 2006-10-25 | 2011-08-16 | Newlink Genetics Corporation | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes |
| MX2010013059A (en) | 2008-05-30 | 2010-12-20 | Glycofi Inc | Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose. |
| UA109633C2 (en) | 2008-12-09 | 2015-09-25 | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
| KR20120101059A (en) | 2009-11-11 | 2012-09-12 | 모멘타 파머슈티컬스 인코포레이티드 | Glycosyl transferase from chinese hamster and related methods |
| US9068011B2 (en) | 2010-03-10 | 2015-06-30 | Genmab A+S | Monoclonal antibodies against c-Met |
| CA2800785C (en) | 2010-05-27 | 2019-09-24 | Genmab A/S | Monoclonal antibodies against her2 |
| CN103153339B (en) | 2010-05-27 | 2021-05-04 | 根马布股份公司 | Monoclonal antibodies against HER2 epitope |
| RS59769B1 (en) | 2010-06-09 | 2020-02-28 | Genmab As | Antibodies against human cd38 |
| HRP20171789T1 (en) | 2010-06-15 | 2017-12-29 | Genmab A/S | HUMAN ANTIBODY ANTIBODIES CONJUGATES WITH TISSUE FACTOR |
| EP2699260B1 (en) | 2011-04-20 | 2024-11-20 | Genmab A/S | Bispecifc antibodies against her2 |
| JP2014514314A (en) | 2011-04-20 | 2014-06-19 | ゲンマブ エー／エス | Bispecific antibodies against HER2 and CD3 |
| JP6177231B2 (en) | 2011-04-20 | 2017-08-09 | ゲンマブ エー／エス | Bispecific antibody against HER2 |
| WO2016089610A1 (en) | 2014-12-06 | 2016-06-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for cancer immunotherapy |
| CA2973159A1 (en) | 2015-01-08 | 2016-07-14 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| GB201505860D0 (en) | 2015-04-07 | 2015-05-20 | Agalimmune Ltd | Therapeutic compositions and methods of use for treating cancer |
| EP3585403A4 (en) | 2017-02-22 | 2020-12-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TIM3 BINDING CHIMERA ANTIGEN RECEPTORS |
| MX2019015484A (en) | 2017-07-07 | 2020-07-28 | H Lee Moffitt Cancer Ct & Res | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COESTIMULATOR DOMAINS. |
| AU2019205422B2 (en) | 2018-01-08 | 2025-08-28 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting CD99-expressing cancers |
| BR112020013954A2 (en) | 2018-01-09 | 2020-12-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | compositions and methods for targeting cancers that express clec12a |
| US20220202885A1 (en) * | 2019-06-27 | 2022-06-30 | Bionoxx Inc. | Oncolytic virus with improved safety and anticancer effects |
| EP4069245A1 (en) | 2019-12-02 | 2022-10-12 | Celgene Corporation | Therapy for the treatment of cancer |
| EP4110319B1 (en) | 2020-02-27 | 2026-01-07 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Tumor-infiltrating lymphocytes with enhanced tumor reactivity |
| KR20230025662A (en) | 2020-05-05 | 2023-02-22 | 리제너론 파마슈티칼스 인코포레이티드 | CARs containing CD28 zeta and CD3 zeta |
| CN115960244A (en) * | 2021-09-14 | 2023-04-14 | 上海鸣大生物科技有限公司 | Recombinant alpha-1, 3-galactosyltransferase as well as preparation method and application thereof |
| WO2024206155A1 (en) | 2023-03-24 | 2024-10-03 | Cornell University | Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6241982B1 (en) | 1988-03-21 | 2001-06-05 | Chiron Corporation | Method for treating brain cancer with a conditionally lethal gene |
| US6133029A (en) | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
| CN1038306A (en) | 1988-03-21 | 1989-12-27 | 维吉恩公司 | Recombinant retroviruses |
| US5068191A (en) | 1989-08-31 | 1991-11-26 | The Biomembrane Institute | Purified histo-blood group a glycosyltransferase and antibodies thereto |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| CA2157659C (en) | 1993-03-16 | 2003-10-21 | Mauro S. Sandrin | Use of porcine gal .alpha. (1,3) galactosyl transferase in xenograft therapies |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US5849991A (en) | 1994-01-27 | 1998-12-15 | Bresatch Limited | Mice homozygous for an inactivated α 1,3-galactosyl transferase gene |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6197293B1 (en) | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| AU6691496A (en) | 1995-08-01 | 1997-02-26 | Advanced Therapies, Inc. | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
| AUPN912396A0 (en) * | 1996-04-03 | 1996-05-02 | St. Vincent's Hospital (Melbourne) Limited | Complement mediated rejection of transfected tumour cells |
| US6183993B1 (en) * | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
| WO1998014593A2 (en) | 1996-10-01 | 1998-04-09 | Geron Corporation | Human telomerase catalytic subunit |
| US5869035A (en) * | 1996-11-13 | 1999-02-09 | Human Gene Therapy Research Institute | Methods and compositions for inducing complement destruction of tissue |
| WO1998026747A2 (en) * | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
| US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| WO1999024584A1 (en) * | 1997-11-12 | 1999-05-20 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| AU1606999A (en) | 1997-11-26 | 1999-06-15 | Albert Einstein College Of Medicine Of Yeshiva University | Mouse telomerase reverse transcriptase |
| DE19757984A1 (en) | 1997-12-24 | 1999-07-01 | Bayer Ag | Regulatory DNA sequences from the 5 'region of the gene of the human catalytic telomerase subunit and their diagnostic and therapeutic use |
| AU761567B2 (en) | 1999-02-04 | 2003-06-05 | Geron Corporation | Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer |
| WO2001088096A2 (en) | 2000-05-15 | 2001-11-22 | Geron Corporation | Ovine tissue for xenotransplantation |
-
2001
- 2001-11-26 AU AU2002235141A patent/AU2002235141A1/en not_active Abandoned
- 2001-11-26 US US09/994,427 patent/US6713055B2/en not_active Expired - Fee Related
- 2001-11-26 WO PCT/US2001/044306 patent/WO2002042468A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US6713055B2 (en) | 2004-03-30 |
| WO2002042468A2 (en) | 2002-05-30 |
| US20020128221A1 (en) | 2002-09-12 |
| WO2002042468A3 (en) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002235141A1 (en) | Glycosyltransferase vectors for treating cancer | |
| AU2001227966A1 (en) | Methods for treating tumors | |
| AU2002324574A1 (en) | Methods for treating prostatitis | |
| AU2002247304A1 (en) | Anti-neovasculature preparations for cancer | |
| AU2001293150A1 (en) | Electromagnetic antenna apparatus | |
| AU2001245283A1 (en) | Methods for treating aneurysms | |
| AU2001255602A1 (en) | Methods for treating bone tumors | |
| AUPR395801A0 (en) | Antibodies against cancer | |
| EP1176964B8 (en) | Uses of et743 for treating cancer | |
| AU2002225930A1 (en) | Methods for treating phosphatide-containing mixtures | |
| AU6352101A (en) | Apparatus for electromagnetic spectroscopy | |
| AU2001290860A1 (en) | Spas-1 cancer antigen | |
| AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
| AU2001232054A1 (en) | Vector | |
| AUPR152100A0 (en) | Method for treating coral | |
| AU2002308642A1 (en) | Methods for treating cancer | |
| AU2001253836A1 (en) | Method of treating cancer | |
| AU2002236517A1 (en) | Targetet retoviral vectors for cancer immunotherapy | |
| AU2002257458A1 (en) | Mage-a1 peptides for treating or preventing cancer | |
| AU2001257325A1 (en) | Cancer treatment | |
| AU2001236470A1 (en) | Ovarian tumor-associated sequences | |
| AU2001294866A1 (en) | Transferases | |
| AU7936898A (en) | Vectors for treating cancer | |
| AU4672401A (en) | Vectors | |
| AU3427800A (en) | Process for preparing cross-linked polyolefins |